Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease

BackgroundOsimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in treating non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, EGFR-TKI-induced interstitial lung disease (ILD) is a recog...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hejing Bao, Caijiu Deng, Xi Luo, Haoran Su, Hehong Bao, Jiazhu Hu, Xiaolong Cao, Liping Lin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-04-01
Edice:	Frontiers in Pharmacology
Témata:	aumolertinib EGFR-TKI interstitial lung disease non-small cell lung cancer osimertinib
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1785616/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!